CA2405900A1 - Test de diagnostic de polypeptide inhibiteur gastrique destine a la detection de la sensibilite aux diabetes de type 2, a une intolerance au glucose, ou a une glycemie a jeun - Google Patents

Test de diagnostic de polypeptide inhibiteur gastrique destine a la detection de la sensibilite aux diabetes de type 2, a une intolerance au glucose, ou a une glycemie a jeun Download PDF

Info

Publication number
CA2405900A1
CA2405900A1 CA002405900A CA2405900A CA2405900A1 CA 2405900 A1 CA2405900 A1 CA 2405900A1 CA 002405900 A CA002405900 A CA 002405900A CA 2405900 A CA2405900 A CA 2405900A CA 2405900 A1 CA2405900 A1 CA 2405900A1
Authority
CA
Canada
Prior art keywords
gip
individual
diabetes
type
glucose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002405900A
Other languages
English (en)
Inventor
Michael A. Nauck
Juris J. Meier
Katrin Huecking
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Restoragen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2405900A1 publication Critical patent/CA2405900A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Abstract

L'invention concerne des méthodes et des kits permettant de déterminer si un individu est susceptible de développer une intolérance au glucose (IGT), une glycémie à jeun (IFG), ou des diabètes de type 2. Ces méthodes consistent à administrer un polypeptide inhibiteur gastrique ou un variant de polypeptide inhibiteur gastrique et une substance nutritive à un individu, mesurer la réponse de l'individu et déterminer si cet individu est susceptible de développer une intolérance au glucose (IGT), des diabètes de type 2 ou une glycémie à jeun (IFG).
CA002405900A 2000-04-27 2001-04-26 Test de diagnostic de polypeptide inhibiteur gastrique destine a la detection de la sensibilite aux diabetes de type 2, a une intolerance au glucose, ou a une glycemie a jeun Abandoned CA2405900A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55977900A 2000-04-27 2000-04-27
US09/559,779 2000-04-27
PCT/US2001/013378 WO2001081919A2 (fr) 2000-04-27 2001-04-26 Test de diagnostic de polypeptide inhibiteur gastrique destine a la detection de la sensibilite aux diabetes de type 2, a une intolerance au glucose, ou a une glycemie a jeun

Publications (1)

Publication Number Publication Date
CA2405900A1 true CA2405900A1 (fr) 2001-11-01

Family

ID=24234987

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002405900A Abandoned CA2405900A1 (fr) 2000-04-27 2001-04-26 Test de diagnostic de polypeptide inhibiteur gastrique destine a la detection de la sensibilite aux diabetes de type 2, a une intolerance au glucose, ou a une glycemie a jeun

Country Status (5)

Country Link
EP (1) EP1356295A2 (fr)
KR (1) KR20020097236A (fr)
AU (1) AU2001257278A1 (fr)
CA (1) CA2405900A1 (fr)
WO (1) WO2001081919A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
EP1853627A2 (fr) * 2005-02-11 2007-11-14 Amylin Pharmaceuticals, Inc. Analogues de gip et polypeptides hybrides de gip aux proprietes selectionnables
WO2007056362A2 (fr) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Analogues de glucagon a solubilite et a stabilite physiologiques ameliorees
EP1857818A1 (fr) * 2006-05-15 2007-11-21 DIGILAB BioVisioN GmbH Diagnostic et usages thérapeutiques des peptides pour les formes de diabète précoces de type 2 et les conditions correspondantes
EP2059818A2 (fr) * 2006-05-15 2009-05-20 Digilab, Inc. Biomarqueurs pour une préforme de diabète de type 2 et méthodes de détection de la présence ou de l'absence d'une préforme du diabète de type 2
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
WO2008086086A2 (fr) 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Analogues de glucagon présentant une solubilité améliorée dans des tampons à ph physiologiques
EA017849B1 (ru) 2007-02-15 2013-03-29 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Соагонисты глюкагоновых/glp-1-рецепторов
EP2214691B1 (fr) 2007-10-30 2015-09-30 Indiana University Research and Technology Corporation Composés présentant une activité d'antagoniste de glucagon et d'agoniste du glp-1
ES2509883T3 (es) 2007-10-30 2014-10-20 Indiana University Research And Technology Corporation Antagonistas de glucagón
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
ES2579502T3 (es) 2008-06-17 2016-08-11 Indiana University Research And Technology Corporation Coagonistas de receptores de glucagón/GLP-1
ES2650038T3 (es) 2008-06-17 2018-01-16 Indiana University Research And Technology Corporation Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
SG172291A1 (en) 2008-12-19 2011-07-28 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs
JP5887265B2 (ja) 2009-06-16 2016-03-16 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション Ｇｉｐ受容体活性グルカゴン化合物
EP2512503A4 (fr) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp Co-agonistes du récepteur du glucagon/glp-i
RU2012136450A (ru) 2010-01-27 2014-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения
CA2797095A1 (fr) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Peptides de la superfamille des glucagons presentant une activite de recepteur nucleaire d'hormone
BR112012028707A2 (pt) 2010-05-13 2019-09-24 Univ Indiana Res & Tech Corp composto de glucagon da superfamília de peptídeos exibindo atividade do receptor g com proteína acoplada, pró farmaco, dímero ou multímro, composição farmacêutica que o compreendem e método de administração do mesmo.
KR20130102470A (ko) 2010-06-24 2013-09-17 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그
EA201390941A1 (ru) 2010-12-22 2013-12-30 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, проявляющие активность на рецепторе gip
US9309301B2 (en) 2011-06-22 2016-04-12 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
GEP20176629B (en) 2011-06-22 2017-02-27 Indiana Unversity Research And Tech Corporation Glucagon/glp-1 receptor co-agonists
CA2847246A1 (fr) 2011-11-17 2013-05-23 Indiana University Research And Technology Corporation Peptides de la superfamille du glucagon presentant une action sur les recepteurs aux glucocorticoides
MX2014015558A (es) 2012-06-21 2015-03-05 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben actividad del receptor gip.
EP3693738A1 (fr) * 2013-09-20 2020-08-12 Astute Medical, Inc. Procédés et compositions pour le diagnostic et le pronostic de l'appendicite et la différenciation des causes de la douleur abdominale
US10317359B2 (en) 2016-01-05 2019-06-11 Ravi Kumar Meruva Differential carbon dioxide sensor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04145099A (ja) * 1990-10-05 1992-05-19 Sanwa Kagaku Kenkyusho Co Ltd Ｇｉｐ様活性を有するポリペプチド誘導体及びその用途

Also Published As

Publication number Publication date
EP1356295A2 (fr) 2003-10-29
WO2001081919A3 (fr) 2003-04-24
AU2001257278A1 (en) 2001-11-07
KR20020097236A (ko) 2002-12-31
WO2001081919A2 (fr) 2001-11-01

Similar Documents

Publication Publication Date Title
CA2405900A1 (fr) Test de diagnostic de polypeptide inhibiteur gastrique destine a la detection de la sensibilite aux diabetes de type 2, a une intolerance au glucose, ou a une glycemie a jeun
Meier et al. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes
Meier et al. Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes
Vilsbøll et al. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients
CN1942767A (zh) 对2型糖尿病、葡萄糖耐量低减、空腹血糖异常的易感性测定的肠抑胃肽判断试验
DeFronzo et al. Preservation of β-cell function: the key to diabetes prevention
Vilsbøll et al. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide—regardless of etiology and phenotype
DeFronzo et al. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake
Gavin III et al. Report of the expert committee on the diagnosis and classification of diabetes mellitus
World Health Organization Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus
Alberti et al. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation
Lebovitz Insulin resistance: definition and consequences
Yabe et al. Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients
Meier et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes
Knop et al. The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance
Trischitta et al. Defects in insulin-receptor internalization and processing in monocytes of obese subjects and obese NIDDM patients
US8367418B2 (en) Method and system to provide personalized pharmaceutical compositions and dosages
Calanna et al. Alpha-and beta-cell abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes
Meier et al. Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects
SMITH et al. Appearance of type II diabetes mellitus in type I diabetic recipients of pancreas allografts
Schou et al. Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight
Schrader et al. Impaired glucose-induced glucagon suppression after partial pancreatectomy
Ilag et al. Reduced pancreatic polypeptide response to hypoglycemia and amylin response to arginine in subjects with a mutation in the HNF-4alpha/MODY1 gene.
Nandhini et al. Definition, diagnostic criteria, screening, diagnosis, and classification of diabetes and categories of glucose intolerance
WO2002085406A1 (fr) Procedes et compositions pour le traitement d'etats lies a la resistance a l'insuline

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead